このエントリーをはてなブックマークに追加
ID 48855
フルテキストURL
著者
Huang, P Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaku, H Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Chen, J Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kashiwakura, Y Innovation Center Okayama for Nanobio-Targeted Therapy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Saika, T Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Nasu, Y Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Urata, Y Oncolys BioPharma Inc.
Fujiwara, T Center for Gene and Cell Therapy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID 科研費研究者番号
Watanabe, M Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kumon, H Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
抄録
OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301- or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.
キーワード
renal cell carcinoma
OBP-301
adenovirus
hTERT
interleukin-2
発行日
2010-07
出版物タイトル
Cancer Gene Therapy
17巻
7号
出版者
Nature Publishing Group
開始ページ
484
終了ページ
491
ISSN
0929-1903
NCID
AA12570566
資料タイプ
学術雑誌論文
プロジェクト
ナノバイオ標的医療の融合的創出拠点
オフィシャル URL
http://www.nature.com/cgt/journal/v17/n7/full/cgt20105a.html
言語
English
著作権者
© Nature Publishing Group
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT